WST · CIK 105770
What West Pharmaceutical Services, Inc. told the SEC could break it.
West Pharmaceutical's disclosures center on the inputs of its drug-packaging and delivery components and on customer concentration. Many of its proprietary products are made from synthetic elastomers derived from petroleum, bought largely under long-term contracts whose surcharges track crude oil prices, and it depends on single-source suppliers for certain critical raw materials that — given FDA qualification requirements — are slow and costly to replace. On the demand side, one customer was 15.8% of 2025 net sales ($485.9 million) and its ten largest were 47.6%, while its globally distributed manufacturing and supplier base (most sales and many facilities sit outside the U.S.) leaves it exposed to new U.S. and retaliatory tariffs.
4 self-disclosed vulnerabilities, pulled from its own filings — each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Commodity & input dependence
- synthetic elastomers / crude oilmedium
Many proprietary products are made from synthetic elastomers derived from petroleum refining; long-term supply contracts carry surcharges tied to crude oil prices, hedged with crude call options (184,075 bbl outstanding).
“Many of our proprietary products are made from synthetic elastomers, which are derived from the petroleum refining process. We purchase the majority of our elastomers via long-term supply contracts, some of which contain clauses that provide for surcharges related to fluctuations in crude oil prices.”
Customer concentration
- single >10% customer (15.8% of net sales)medium
One unnamed customer accounted for 15.8% ($485.9M) of consolidated net sales in 2025 across both segments — up from 12.3% (2024) and 10.9% (2023); ten largest customers were 47.6%.
“Our ten largest customers accounted for 47.6% of our consolidated net sales in 2025, and one of these customers individually accounted for more than 10% of consolidated net sales, at 15.8% or $485.9 million, contributing to net sales in both the Proprietary and Contract Manufacturing reporting segments.”
SEC filing →As of 2026
Regulatory & policy
- US and retaliatory tariffsmedium
New US tariffs and retaliatory tariffs by other jurisdictions affect West's globally distributed manufacturing and supplier base (56.7% of sales and many facilities/suppliers are outside the US).
“In recent months, the U.S. government has imposed additional tariffs and trade restrictions on certain goods produced outside of the United States. In response to these actions, certain jurisdictions in which we operate have imposed or are considering imposing tariffs and restrictions on certain goods produced in the United States.”
Sole-source dependency
- single-source critical raw materialsmedium
West relies on single-source suppliers for certain critical raw materials; FDA qualification requirements make replacement sources slow and costly, so a supply interruption could be material.
“Due to quality and regulatory control over our production processes, single source availability, and the quality and regulatory burden required in qualifying suppliers, we rely on single-source suppliers for certain critical raw materials.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings — including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
“infusor is made by West Pharmaceutical Services, Inc.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch